Clinical Trials Arena June 6, 2024
Novo Nordisk senior vice president Thomas Senderovitz said that big pharma needs to have more involvement in AI regulation.
Pharmaceutical companies need more involvement with agencies as they develop AI regulations.
At the Veeva R&D Summit at the Marriott Madrid Auditorium, Novo Nordisk senior vice president Thomas Senderovitz said that pharma companies need to have more involvement as agencies develop these regulations.
Senderovitz is working with partners from other pharmaceutical companies, including James Weatherall, vice president of data science and AI in the R&D department at AstraZeneca, to try and work with the agencies as they construct guidance.
“The challenge is that you have different regulatory systems that do not always have the same view,” Senderovitz explained.
“In Europe, you...
Today's Sponsors
Today's Sponsor